Staten Biotechnology in $430m deal with Novo Nordisk
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Entries by Thomas Gabrielczyk
Kurma Partners announce closing of Biofund III
Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise €150m.
MEPs back €120bn budget for Horizon Europe
The European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
New cheap CRS-blockers at the horizon
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.
Are novel antibiotics worth investing in?
In autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the screen, discussion about which pull mechanism should be started first is in full swing. Meanwhile, small and medium-sized companies combine forces aiming to propel preclinical and early clinical R&D.
Oxford BioTherapeutics in $450 deal with Wuxi Biologics
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics’ WuXiBody platform.
Diabetes doubles risk for heart failure
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
AZ checkpoint blocker combo fails in head and neck cancer
British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
XyloCor Therapeutics bags US$17m in Series A financing
LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
Uncommon mutations affect breast cancer prognosis
Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.